Healthcare

• Management guided to low single-digit constant-currency revenue growth and underlying net profit of $330 million to $350 million, with grossMarginexpected to be similar to FY26.

• CSL Behring, which supplies plasma-derived therapies and recombinant products, generated US$11.4bn, down 1%.

• Non-resident policy units, which cover international students and workers, fell 2.3%, mainly because tighter migration settings reduced student numbers.

• In compassionate use after ruxolitinib failure, 76% of patients were alive at day 100, compared with roughly 20% to 30% survival for other third-line agents cited by the company.

• The policy is a semi-annual payout of 70% to 100% of an "Available Pool", defined as after-tax royalty income less corporate costs.

• International UOP rose 15.1% to $35.1 million, with policyholder growth of 4.4% and a netMarginof about 15%.

• The company reported signing 10 new contracts worth at least $407 million, including a 10-year agreement with UC Health in Colorado.